U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07950007) titled 'ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast Cancer' on Nov. 13.
Brief Summary: The convergence of evidence from neoCARHP (comparable pCR between TCHP and THP in an unselected population), DB-11 (activity of T-DXd-THP in high-risk HER2-positive early breast cancer), and I-SPY2 ctDNA data (early ctDNA clearance predicts favorable response and outcomes) provides a strong rationale for biomarker-guided treatment selection. This study uses early on-treatment ctDNA response after standardized THP induction to direct therapy intensity rather than reflexively escalating all patients.
Unlike non-biomarker-selected escalation approaches...